Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-04-29
Disclosure Type: Material Management Matters Related to Investment Decisions (Amendment)
💡 3-Second Summary
Samsung Biologics has extended the non-disclosure period regarding the identity of its client for a KRW 107.5 billion biopharmaceutical contract manufacturing organization (CMO) Letter of Intent (LOI) with a European pharmaceutical company, moving the expiration date from April 30 to May 31 following mutual consultations.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Contract Details: Signing of a Letter of Intent (LOI) for a biopharmaceutical contract manufacturing organization (CMO) contract.
- Counterparty: A pharmaceutical company located in Europe (Identity withheld due to management confidentiality).
- Contract Amount: KRW 107,513,583,360 (Approx. KRW 107.5B)
- This figure was determined by applying the initial exchange rate of 1,325.60 KRW/USD on the LOI signing date (May 30, 2023) to the fixed contract amount of USD 81,105,600.
- The amount represents 3.58% of Samsung Biologics’ recent annual revenue (KRW 3,001,295,197,683).
- Amendment Details (Extension of Non-Disclosure Period):
- (Before) Expiration Date 2024-04-30 → (After) Expiration Date 2024-05-31
- The non-disclosure period concerning the counterparty has been extended by one month following consultations with the client.
- Other Conditions: The terms of this LOI are legally binding on both parties, and the finalized details will be formally disclosed upon the execution of the main contract. The contract period runs from the signing date of the LOI until the execution of the main contract.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: This disclosure involves a minor adjustment extending the regulatory non-disclosure timeline for an existing KRW 107.5 billion LOI (3.58% of annual revenue), meaning it does not prompt any immediate changes to short-term financial fundamentals. However, because the agreement carries legally binding power, it remains an active revenue pipeline that could eventually transition into a definitive commercial contract.
- Risks and Red Flags for Investors: While the adjustment constitutes a temporary timeline extension (from late April to late May) rather than a cancellation or scale reduction, the non-disclosure period has undergone sequential extensions since the initial signing on May 30, 2023. The filing does not specify the concrete reasons or structural difficulties behind the timeline adjustments, so market participants should avoid speculative conclusions. This continuing anonymity and unfinalized main contract timeline may introduce brief uncertainty, emphasizing the need to track subsequent regulatory filings leading up to the new May 31 deadline.
📝 Editor’s Comment (by K-STOCK Editor)
In large-scale manufacturing procurement for domestic bio-companies, utilizing the regulatory “non-disclosure option” to temporarily withhold a client’s identity for management confidentiality is a standard administrative procedure. However, the fact that this specific non-disclosure period has been repeatedly adjusted through regulatory updates since the initial LOI may incline market participants to maintain a cautious stance. Since a new target timeline of May 31 has been established, analytical priority should be placed on tracking whether a formalized main contract or further regulatory amendments materialize as the new deadline approaches.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
